(Q34843826)

English

The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype (English)

1 reference

Europe PubMed Central

4 August 2017

misclassification

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Caporaso NE

1

1 reference

Europe PubMed Central

4 August 2017

Shields PG

2

1 reference

Europe PubMed Central

4 August 2017

Landi MT

3

1 reference

Europe PubMed Central

4 August 2017

Shaw GL

4

1 reference

Europe PubMed Central

4 August 2017

Tucker MA

5

1 reference

Europe PubMed Central

4 August 2017

Hoover R

6

1 reference

Europe PubMed Central

4 August 2017

Sugimura H

7

1 reference

Europe PubMed Central

4 August 2017

Weston A

8

1 reference

Europe PubMed Central

4 August 2017

Harris CC

9

1 reference

Europe PubMed Central

4 August 2017

publication date

1 November 1992

1 reference

Europe PubMed Central

4 August 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

Environmental Health Perspectives

1 reference

Europe PubMed Central

4 August 2017

98

1 reference

Europe PubMed Central

4 August 2017

101-105

1 reference

Europe PubMed Central

4 August 2017

Familial aggregation of lung cancer among hospital patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Increased familial risk for lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Debrisoquine metabolism and genetic predisposition to lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Lung cancer and the debrisoquine metabolic phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Identification of the primary gene defect at the cytochrome P450 CYP2D locus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Molecular genetics of the debrisoquin-sparteine polymorphism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

The metabolism of [14C]-debrisoquine in man

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

8 July 2018

Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1519603

26 October 2018

Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1362537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

1 reference

https://pubmed.ncbi.nlm.nih.gov/1362537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

1 reference

https://pubmed.ncbi.nlm.nih.gov/1362537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polymorphic oxidation of debrisoquine in lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1362537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1362537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/1362537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1289/EHP.9298101

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34843826&oldid=1777516721"